The bispecific, tetravalent fibroblast-activation protein (FAP)-TRAIL-R2 antibody, RG7386, targets cancer-associated fibroblasts in the tumour stroma and TRAIL-R2 on tumour cells simultaneously thereby inducing higher-order clustering and apoptosis induction in vitro and animal models. The gene discussed is TNFRSF10B; the disease is neoplasm.